Literature DB >> 26059061

Splitting livers: Trans-hilar or trans-umbilical division? Technical aspects and comparative outcomes.

J de Ville de Goyet1,2, F di Francesco1, V Sottani1, C Grimaldi1, A E Tozzi3, L Monti4, P Muiesan5.   

Abstract

UNLABELLED: Controversy remains about the best line of division for liver splitting, through Segment IV or through the umbilical fissure. Both techniques are currently used, with the choice varying between surgical teams in the absence of an evidence-based choice. We conducted a single-center retrospective analysis of 47 left split liver grafts that were procured with two different division techniques: "classical" (N = 28, Group A) or through the umbilical fissure and plate (N = 19, Group B). The allocation of recipients to each group was at random; a single transplant team performed all transplantations. Demographics, characteristics, technical aspects, and outcomes were similar in both groups. The grafts in Group A, prepared with the classical technique, were procured more often with a single BD orifice compared with the grafts in Group B; however, this was not associated with a higher incidence of biliary problems in this series of transplants (96% actual graft survival rate [median ± s.d. FOLLOW-UP: 26 ± 20 months]). Both techniques provide good quality split grafts and an excellent outcome; surgical expertise with a given technique is more relevant than the technique itself. The classical technique, however, seems to be more flexible in various ways, and surgeons may find it to be preferable.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Keywords:  complications of liver transplantation; donor hepatectomy; pediatric liver transplantation; practice guidelines

Mesh:

Year:  2015        PMID: 26059061     DOI: 10.1111/petr.12534

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  1 in total

Review 1.  Imaging in pediatric liver transplantation.

Authors:  L Monti; G Soglia; P Tomà
Journal:  Radiol Med       Date:  2016-02-24       Impact factor: 3.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.